How do unsafe drugs reach the marketplace? Is the Food and Drug Administration overwhelmed by the supply and demand for drugs and incapable of guaranteeing the safety of the four billion prescriptions our pharmacies will fill this year? Also, Congress sees evidence of a Syrian reactor six months late, and with more states up for grabs in November, Democrats and Republicans will have to change their Electoral College strategies. Lawrence O'Donnell guest hosts.
FROM THIS EPISODE
The CIA is showing Congressional committees a video today that reportedly shows North Korean involvement in the construction of a nuclear facility in Syria last summer. The Israeli government relied on this video evidence in its decision to bomb the facility on September 6. Jay Solomon is chief foreign affairs correspondent for the Wall Street Journal.
With 80 people dead after using a contaminated blood thinner imported from China, the head of the Food and Drug Administration faced withering cross examination from a Congressional subcommittee this week. If a drug is tested by scientists, does that mean it's safe? What if the scientists took money from the company that made the drug? Would more oversight slow down the process too much? Shouldn't the FDA be able to guarantee the safety of our prescriptions?
Peter Pitts, former Associate Commissioner, Food and Drug Administration
Eric Meslin, Director of the Center for Bioethics, Indiana University
Phil Fontanarosa, Executive Deputy Director, Journal of the American Medical Association
John "Jack" Calfee, Resident Scholar, American Enterprise Institute
Will California be a red state in November? Can the democrats win in the south this time? With more states up for grabs in November, both Democrats and Republicans are reworking their Electoral College strategies. Gerry Seib, executive Washington editor for the Wall Street Journal, is co-author of Pennsylvania Avenue: Profiles in Backroom Power.
Gerald Seib and John Harwood